XML 106 R92.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Schedule of Segment Perfomance Measures by Segment) (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2017
[1],[2]
Mar. 31, 2017
[2],[3]
Dec. 31, 2016
[2]
Sep. 30, 2016
[4]
Jun. 30, 2016
[5]
Mar. 31, 2016
[6]
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Segment Reporting Information [Line Items]                      
Net sales $ 194,620 $ 190,128 $ 125,552 $ 128,018 $ 135,424 $ 157,926 $ 131,674 $ 133,500 $ 638,318 $ 558,524 $ 546,951
Gross profit $ 36,829 $ 42,319 $ 30,805 $ 30,839 $ 34,047 $ 38,289 $ 35,868 $ 34,581 140,792 142,785 135,434
Income before income taxes                 17,361 53,854 53,865
Operating Segments | Human Health                      
Segment Reporting Information [Line Items]                      
Net sales                 315,395 228,035 225,263
Gross profit                 78,109 77,880 75,749
Income before income taxes                 15,434 36,362 35,152
Operating Segments | Pharmaceutical Ingredients                      
Segment Reporting Information [Line Items]                      
Net sales                 157,445 161,011 149,296
Gross profit                 25,474 28,752 26,683
Income before income taxes                 9,322 11,856 8,697
Operating Segments | Performance Chemicals                      
Segment Reporting Information [Line Items]                      
Net sales                 165,478 169,478 172,392
Gross profit                 37,209 36,153 33,002
Income before income taxes                 18,829 17,799 14,289
Unallocated Corporate                      
Segment Reporting Information [Line Items]                      
Net sales                
Gross profit                
Income before income taxes                 $ (26,224) $ (12,163) $ (4,273)
[1] Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.
[2] Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.
[3] Includes pretax item of $733 environmental remediation charge in connection with Arsynco.
[4] Includes pretax item of $170 environmental remediation charge in connection with Arsynco.
[5] Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.
[6] Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.